Ledaga (Chlormethine)
chlormethine 0.016% (160 microgram/g) gel, 60 g · APPLICATION · PBS code 14658L
AUTHORITY_REQUIREDWhat it costs
AU$1622.09 PBS-determined price per 2 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2024-11-01.
- • Repeats: 5.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Mycosis fungoides cutaneous T-cell lymphoma
Initial treatment
The condition must be any of: (i) Stage IA, (ii) IIA, (iii) IB mycosis fungoides cutaneous T-cell lymphoma; AND
The condition must have been confirmed through a diagnostic lesion biopsy from an Approved Pathology Authority; AND
The condition must cover either of which: (i) no more than 10% of the patient's body surface area, (ii) no more than 25% of the patient's body surface area; AND
Patient must be treated by at least one of the following prescriber types (i) dermatologist, (ii) haematologist; AND
The treatment must be approved for 1 unit if the condition is no more than 10% of the patient's body surface area to provide 4 weeks of treatment per script; or
The treatment must be approved for 2 units if the condition is no more than 25% of the patient's body surface area to provide 4 weeks of treatment per script; AND
Patient must be at least 18 years of age.
Confirmation of eligibility for treatment with diagnostic reports must be documented in the patient's medical records.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Mycosis fungoides cutaneous T-cell lymphoma
Continuing treatment
Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND
Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition; AND
Patient must be treated by at least one of the following prescriber types (i) dermatologist, (ii) haematologist; AND
The treatment must be approved for 1 unit if the condition is no more than 10% of the patient's body surface area to provide 4 weeks of treatment per script; or
The treatment must be approved for 2 units if the condition is no more than 25% of the patient's body surface area to provide 4 weeks of treatment per script.
Sponsor: Arrotex Pharmaceuticals Pty Ltd ABN 30 605 552 234
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.